{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:33Z","timestamp":1791232413242,"version":"4.1.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10741-020-09940-0","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T10:43:50Z","timestamp":1584528230000},"page":"1081-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Non-ischemic dilated cardiomyopathy and cardiac fibrosis"],"prefix":"10.1007","volume":"26","author":[{"given":"Bianca Olivia","family":"Cojan-Minzat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Zlibut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9224-9134","authenticated-orcid":false,"given":"Lucia","family":"Agoston-Coldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"9940_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIRCRESAHA.117.309711","volume":"121","author":"WJ McKenna","year":"2017","unstructured":"McKenna WJ, Maron BJ, Thiene G (2017) Classification, epidemiology, and global burden of cardiomyopathies. Circ Res 121:722\u2013730. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.309711","journal-title":"Circ Res"},{"key":"9940_CR2","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","volume":"37","author":"YM Pinto","year":"2016","unstructured":"Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, B\u00f6hm M, Duboc D, Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S, Zamorano JL, Caforio ALP, Charron P (2016) Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 37:1850\u20131858. https:\/\/doi.org\/10.1093\/eurheartj\/ehv727","journal-title":"Eur Heart J"},{"key":"9940_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5339\/gcsp.2012.4","volume":"2012","author":"F Cecchi","year":"2012","unstructured":"Cecchi F, Tomberli B, Olivotto I (2012) Clinical and molecular classification of cardiomyopathies. Glob Cardiol Sci Pract 2012:4. https:\/\/doi.org\/10.5339\/gcsp.2012.4","journal-title":"Glob Cardiol Sci Pract"},{"key":"9940_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1172\/JCI200524351","volume":"115","author":"H Morita","year":"2005","unstructured":"Morita H, Seidman J, Seidman CE (2005) Genetic causes of human heart failure. J Clin Invest 115:518\u2013526. https:\/\/doi.org\/10.1172\/JCI200524351","journal-title":"J Clin Invest"},{"key":"9940_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ehf2.12041","volume":"2","author":"JV Venero","year":"2015","unstructured":"Venero JV, Doyle M, Shah M, Rathi VK, Yamrozik JA, Williams RB, Vido DA, Rayarao G, Benza R, Murali S, Glass J, Olson P, Sokos G, Biederman RWW (2015) Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy-preliminary observations from a high-volume transplant centre. ESC Hear Fail 2:150\u2013159. https:\/\/doi.org\/10.1002\/ehf2.12041","journal-title":"ESC Hear Fail"},{"key":"9940_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","volume":"71","author":"P Kong","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71:549\u2013574. https:\/\/doi.org\/10.1007\/s00018-013-1349-6","journal-title":"Cell Mol Life Sci"},{"key":"9940_CR7","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1253\/circj.CJ-16-1003","volume":"80","author":"MJ Ivey","year":"2016","unstructured":"Ivey MJ, Tallquist MD (2016) Defining the cardiac fibroblast. Circ J 80:2269\u20132276. https:\/\/doi.org\/10.1253\/circj.CJ-16-1003","journal-title":"Circ J"},{"key":"9940_CR8","doi-asserted-by":"publisher","unstructured":"Legere SA, Haidl ID, L\u00e9gar\u00e9 J-F, Marshall JS (2019) Mast cells in cardiac fibrosis: new insights suggest opportunities for intervention. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.00580","DOI":"10.3389\/fimmu.2019.00580"},{"key":"9940_CR9","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1084\/jem.20161791","volume":"214","author":"T Nevers","year":"2017","unstructured":"Nevers T, Salvador AM, Velazquez F, Ngwenyama N, Carrillo-Salinas FJ, Aronovitz M, Blanton RM, Alcaide P (2017) Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure. J Exp Med 214:3311\u20133329. https:\/\/doi.org\/10.1084\/jem.20161791","journal-title":"J Exp Med"},{"key":"9940_CR10","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1172\/JCI94753","volume":"127","author":"H Khalil","year":"2017","unstructured":"Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, Vagnozzi RJ, Liu R, Huynh T, Lee S-J, Karch J, Molkentin JD (2017) Fibroblast-specific TGF-\u03b2\u2013Smad2\/3 signaling underlies cardiac fibrosis. J Clin Invest 127:3770\u20133783. https:\/\/doi.org\/10.1172\/JCI94753","journal-title":"J Clin Invest"},{"key":"9940_CR11","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.7150\/ijbs.28103","volume":"14","author":"Z-G Ma","year":"2018","unstructured":"Ma Z-G, Yuan Y-P, Wu H-M, Zhang X, Tang Q-Z (2018) Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci 14:1645\u20131657. https:\/\/doi.org\/10.7150\/ijbs.28103","journal-title":"Int J Biol Sci"},{"key":"9940_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia G, Aroor AR, Hill MA, Sowers JR (2018) Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension 72:537\u2013548. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11065","journal-title":"Hypertension"},{"key":"9940_CR13","doi-asserted-by":"publisher","first-page":"e35144","DOI":"10.1371\/journal.pone.0035144","volume":"7","author":"F Ma","year":"2012","unstructured":"Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y, Du J (2012) Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF \u03b2\/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 7:e35144. https:\/\/doi.org\/10.1371\/journal.pone.0035144","journal-title":"PLoS One"},{"key":"9940_CR14","doi-asserted-by":"publisher","unstructured":"Medzikovic L, Aryan L, Eghbali M (2019) Connecting sex differences, estrogen signaling, and microRNAs in cardiac fibrosis. J Mol Med. https:\/\/doi.org\/10.1007\/s00109-019-01833-6","DOI":"10.1007\/s00109-019-01833-6"},{"key":"9940_CR15","doi-asserted-by":"publisher","unstructured":"Richards AM (2017) Circulating biomarkers of cardiac fibrosis. Circ Heart Fail 10. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.003936","DOI":"10.1161\/CIRCHEARTFAILURE.117.003936"},{"key":"9940_CR16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.5114\/aoms.2018.76279","volume":"14","author":"M Michalska-Kasiczak","year":"2018","unstructured":"Michalska-Kasiczak M, Bielecka-Dabrowa A, von Haehling S, Anker SD, Rysz J, Banach M (2018) Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Arch Med Sci 14:890\u2013909. https:\/\/doi.org\/10.5114\/aoms.2018.76279","journal-title":"Arch Med Sci"},{"key":"9940_CR17","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jcmg.2018.03.006","volume":"11","author":"MAJ Becker","year":"2018","unstructured":"Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T (2018) The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy. JACC Cardiovasc Imaging 11:1274\u20131284. https:\/\/doi.org\/10.1016\/j.jcmg.2018.03.006","journal-title":"JACC Cardiovasc Imaging"},{"key":"9940_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.rec.2015.11.011","volume":"69","author":"S Valbuena-L\u00f3pez","year":"2016","unstructured":"Valbuena-L\u00f3pez S, Hinojar R, Puntmann VO (2016) Cardiovascular magnetic resonance in cardiology practice: a concise guide to image acquisition and clinical interpretation. Rev Espa\u00f1ola Cardiol English Ed 69:202\u2013210. https:\/\/doi.org\/10.1016\/j.rec.2015.11.011","journal-title":"Rev Espa\u00f1ola Cardiol English Ed"},{"key":"9940_CR19","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00330-006-0244-z","volume":"16","author":"P Croisille","year":"2006","unstructured":"Croisille P, Revel D, Saeed M (2006) Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside. Eur Radiol 16:1951\u20131963. https:\/\/doi.org\/10.1007\/s00330-006-0244-z","journal-title":"Eur Radiol"},{"key":"9940_CR20","doi-asserted-by":"publisher","unstructured":"Hinderer S, Schenke-Layland K (2019) Cardiac fibrosis \u2013 a short review of causes and therapeutic strategies. Adv Drug Deliv Rev. https:\/\/doi.org\/10.1016\/j.addr.2019.05.011","DOI":"10.1016\/j.addr.2019.05.011"},{"key":"9940_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40824-016-0060-8","volume":"20","author":"Z Fan","year":"2016","unstructured":"Fan Z, Guan J (2016) Antifibrotic therapies to control cardiac fibrosis. Biomater Res 20:13. https:\/\/doi.org\/10.1186\/s40824-016-0060-8","journal-title":"Biomater Res"},{"key":"9940_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.111.030932","volume":"124","author":"RL Montgomery","year":"2011","unstructured":"Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124:1537\u20131547. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.030932","journal-title":"Circulation"},{"key":"9940_CR23","first-page":"596","volume":"14","author":"LM Jaffe","year":"2014","unstructured":"Jaffe LM, Morin DP (2014) Cardiac resynchronization therapy: history, present status, and future directions. Ochsner J 14:596\u2013607","journal-title":"Ochsner J"},{"key":"9940_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jacc.2014.06.1162","volume":"64","author":"R Zusterzeel","year":"2014","unstructured":"Zusterzeel R, Curtis JP, Ca\u00f1os DA, Sanders WE, Selzman KA, Pi\u00f1a IL, Spatz ES, Bao H, Ponirakis A, Varosy PD, Masoudi FA, Strauss DG (2014) Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT. J Am Coll Cardiol 64:887\u2013894. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1162","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-017-0659-5","volume":"113","author":"NM Landry","year":"2018","unstructured":"Landry NM, Cohen S, Dixon IMC (2018) Periostin in cardiovascular disease and development: a tale of two distinct roles. Basic Res Cardiol 113:1. https:\/\/doi.org\/10.1007\/s00395-017-0659-5","journal-title":"Basic Res Cardiol"},{"key":"9940_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC (2016) Cardiac fibrosis. Circ Res 118:1021\u20131040. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306565","journal-title":"Circ Res"},{"key":"9940_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbadis.2016.11.006","volume":"1863","author":"AV Shinde","year":"2017","unstructured":"Shinde AV, Humeres C, Frangogiannis NG (2017) The role of \u03b1-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim Biophys Acta Mol basis Dis 1863:298\u2013309. https:\/\/doi.org\/10.1016\/j.bbadis.2016.11.006","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"9940_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.yjmcc.2016.01.006","volume":"91","author":"KY DeLeon-Pennell","year":"2016","unstructured":"DeLeon-Pennell KY (2016) May the fibrosis be with you: is discoidin domain receptor 2 the receptor we have been looking for? J Mol Cell Cardiol 91:201\u2013203. https:\/\/doi.org\/10.1016\/j.yjmcc.2016.01.006","journal-title":"J Mol Cell Cardiol"},{"key":"9940_CR29","doi-asserted-by":"publisher","first-page":"H1363","DOI":"10.1152\/ajpheart.00395.2013","volume":"305","author":"P Kong","year":"2013","unstructured":"Kong P, Christia P, Saxena A, Su Y, Frangogiannis NG (2013) Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am J Physiol Circ Physiol 305:H1363\u2013H1372. https:\/\/doi.org\/10.1152\/ajpheart.00395.2013","journal-title":"Am J Physiol Circ Physiol"},{"key":"9940_CR30","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.12659\/MSM.906038","volume":"23","author":"L Wang","year":"2017","unstructured":"Wang L, Yue Y, Yang X, Fan T, Mei B, Hou J, Liang M, Chen G, Wu Z (2017) Platelet derived growth factor alpha (PDGFR\u03b1) induces the activation of cardiac fibroblasts by activating c-kit. Med Sci Monit 23:3808\u20133816. https:\/\/doi.org\/10.12659\/MSM.906038","journal-title":"Med Sci Monit"},{"key":"9940_CR31","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2353\/ajpath.2010.090574","volume":"176","author":"P-Y Chu","year":"2010","unstructured":"Chu P-Y, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T, Kaye DM (2010) Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol 176:1735\u20131742. https:\/\/doi.org\/10.2353\/ajpath.2010.090574","journal-title":"Am J Pathol"},{"key":"9940_CR32","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1242\/jcs.001586","volume":"120","author":"X-H Zhao","year":"2007","unstructured":"Zhao X-H, Laschinger C, Arora P, Szaszi K, Kapus A, McCulloch CA (2007) Force activates smooth muscle -actin promoter activity through the Rho signaling pathway. J Cell Sci 120:1801\u20131809. https:\/\/doi.org\/10.1242\/jcs.001586","journal-title":"J Cell Sci"},{"key":"9940_CR33","doi-asserted-by":"publisher","unstructured":"Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD (2017) Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Hear Fail:10. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003688","DOI":"10.1161\/CIRCHEARTFAILURE.116.003688"},{"key":"9940_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.intimp.2016.07.027","volume":"39","author":"CS Abdullah","year":"2016","unstructured":"Abdullah CS, Li Z, Wang X, Jin Z-Q (2016) Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy. Int Immunopharmacol 39:251\u2013264. https:\/\/doi.org\/10.1016\/j.intimp.2016.07.027","journal-title":"Int Immunopharmacol"},{"key":"9940_CR35","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1172\/JCI44824","volume":"121","author":"N Koitabashi","year":"2011","unstructured":"Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA (2011) Pivotal role of cardiomyocyte TGF-\u03b2 signaling in the murine pathological response to sustained pressure overload. J Clin Invest 121:2301\u20132312. https:\/\/doi.org\/10.1172\/JCI44824","journal-title":"J Clin Invest"},{"key":"9940_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.diabres.2017.08.018","volume":"133","author":"Y Yue","year":"2017","unstructured":"Yue Y, Meng K, Pu Y, Zhang X (2017) Transforming growth factor beta (TGF-\u03b2) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract 133:124\u2013130. https:\/\/doi.org\/10.1016\/j.diabres.2017.08.018","journal-title":"Diabetes Res Clin Pract"},{"key":"9940_CR37","doi-asserted-by":"publisher","first-page":"10461","DOI":"10.1074\/jbc.M800902200","volume":"283","author":"R Mishra","year":"2008","unstructured":"Mishra R, Cool BL, Laderoute KR, Foretz M, Viollet B, Simonson MS (2008) AMP-activated protein kinase inhibits transforming growth factor-\u03b2-induced Smad3-dependent transcription and Myofibroblast Transdifferentiation. J Biol Chem 283:10461\u201310469. https:\/\/doi.org\/10.1074\/jbc.M800902200","journal-title":"J Biol Chem"},{"key":"9940_CR38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/jcp.24296","volume":"228","author":"C Wei","year":"2013","unstructured":"Wei C, Kim I-K, Kumar S, Jayasinghe S, Hong N, Castoldi G, Catalucci D, Jones WK, Gupta S (2013) NF-\u03baB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol 228:1433\u20131442. https:\/\/doi.org\/10.1002\/jcp.24296","journal-title":"J Cell Physiol"},{"key":"9940_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCHEARTFAILURE.114.001893","volume":"8","author":"C Duerrschmid","year":"2015","unstructured":"Duerrschmid C, Trial J, Wang Y, Entman ML, Haudek SB (2015) Tumor necrosis factor. Circ Heart Fail 8:352\u2013361. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001893","journal-title":"Circ Heart Fail"},{"key":"9940_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40119-018-0104-3","volume":"7","author":"Y Szekely","year":"2018","unstructured":"Szekely Y, Arbel Y (2018) A review of interleukin-1 in heart disease: where do we stand today? Cardiol Ther 7:25\u201344. https:\/\/doi.org\/10.1007\/s40119-018-0104-3","journal-title":"Cardiol Ther"},{"key":"9940_CR41","doi-asserted-by":"crossref","unstructured":"Lluri G, Deb A (2019) WNT signaling and cardiac fibrosis. Pp 319\u2013334","DOI":"10.1007\/978-3-319-98143-7_11"},{"key":"9940_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41467-017-00840-w","volume":"8","author":"F-L Xiang","year":"2017","unstructured":"Xiang F-L, Fang M, Yutzey KE (2017) Loss of \u03b2-catenin in resident cardiac fibroblasts attenuates fibrosis induced by pressure overload in mice. Nat Commun 8:712. https:\/\/doi.org\/10.1038\/s41467-017-00840-w","journal-title":"Nat Commun"},{"key":"9940_CR43","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1161\/CIRCRESAHA.115.305376","volume":"118","author":"S Menazza","year":"2016","unstructured":"Menazza S, Murphy E (2016) The expanding complexity of estrogen receptor signaling in the cardiovascular system. Circ Res 118:994\u20131007. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.305376","journal-title":"Circ Res"},{"key":"9940_CR44","doi-asserted-by":"publisher","first-page":"e48185","DOI":"10.1371\/journal.pone.0048185","volume":"7","author":"S Kang","year":"2012","unstructured":"Kang S, Liu Y, Sun D, Zhou C, Liu A, Xu C, Hao Y, Li D, Yan C, Sun H (2012) Chronic activation of the G protein-coupled receptor 30 with agonist G-1 attenuates heart failure. PLoS One 7:e48185. https:\/\/doi.org\/10.1371\/journal.pone.0048185","journal-title":"PLoS One"},{"key":"9940_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cvr\/cvs090","volume":"94","author":"H Wang","year":"2012","unstructured":"Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, Groban L (2012) Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc Res 94:96\u2013104. https:\/\/doi.org\/10.1093\/cvr\/cvs090","journal-title":"Cardiovasc Res"},{"key":"9940_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mce.2016.06.018","volume":"434","author":"A Pedram","year":"2016","unstructured":"Pedram A, Razandi M, Narayanan R, Levin ER (2016) Estrogen receptor beta signals to inhibition of cardiac fibrosis. Mol Cell Endocrinol 434:57\u201368. https:\/\/doi.org\/10.1016\/j.mce.2016.06.018","journal-title":"Mol Cell Endocrinol"},{"key":"9940_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/cvr\/cvy185","volume":"115","author":"E Dworatzek","year":"2019","unstructured":"Dworatzek E, Mahmoodzadeh S, Schriever C, Kusumoto K, Kramer L, Santos G, Fliegner D, Leung Y-K, Ho S-M, Zimmermann W-H, Lutz S, Regitz-Zagrosek V (2019) Sex-specific regulation of collagen I and III expression by 17\u03b2-estradiol in cardiac fibroblasts: role of estrogen receptors. Cardiovasc Res 115:315\u2013327. https:\/\/doi.org\/10.1093\/cvr\/cvy185","journal-title":"Cardiovasc Res"},{"key":"9940_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11010-015-2405-3","volume":"405","author":"H Wang","year":"2015","unstructured":"Wang H, Zhao Z, Lin M, Groban L (2015) Activation of GPR30 inhibits cardiac fibroblast proliferation. Mol Cell Biochem 405:135\u2013148. https:\/\/doi.org\/10.1007\/s11010-015-2405-3","journal-title":"Mol Cell Biochem"},{"key":"9940_CR49","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/eurheartj\/ehx808","volume":"39","author":"JAJ Verdonschot","year":"2018","unstructured":"Verdonschot JAJ, Hazebroek MR, Derks KWJ, Barandiar\u00e1n Aizpurua A, Merken JJ, Wang P, Bierau J, van den Wijngaard A, Schalla SM, Abdul Hamid MA, van Bilsen M, van Empel VPM, Knackstedt C, Brunner-La Rocca H-P, Brunner HG, Krapels IPC, Heymans SRB (2018) Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J 39:864\u2013873. https:\/\/doi.org\/10.1093\/eurheartj\/ehx808","journal-title":"Eur Heart J"},{"key":"9940_CR50","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/hmg\/ddw090","volume":"25","author":"M Chatzifrangkeskou","year":"2016","unstructured":"Chatzifrangkeskou M, Le Dour C, Wu W, Morrow JP, Joseph LC, Beuvin M, Sera F, Homma S, Vignier N, Mougenot N, Bonne G, Lipson KE, Worman HJ, Muchir A (2016) ERK1\/2 directly acts on CTGF\/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A\/C gene. Hum Mol Genet 25:2220\u20132233. https:\/\/doi.org\/10.1093\/hmg\/ddw090","journal-title":"Hum Mol Genet"},{"key":"9940_CR51","doi-asserted-by":"publisher","unstructured":"Li W, Yin L, Shen C, Hu K, Ge J, Sun A (2018) SCN5A variants: association with cardiac disorders. Front Physiol 9. https:\/\/doi.org\/10.3389\/fphys.2018.01372","DOI":"10.3389\/fphys.2018.01372"},{"key":"9940_CR52","doi-asserted-by":"publisher","unstructured":"Levick SP, Soto-Pantoja DR, Bi J, Hundley WG, Widiapradja A, Manteufel EJ, Bradshaw TW, Mel\u00e9ndez GC (2018) Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts. Hear Lung Circ. https:\/\/doi.org\/10.1016\/j.hlc.2018.08.003","DOI":"10.1016\/j.hlc.2018.08.003"},{"key":"9940_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1959270","volume":"2016","author":"P Robinson","year":"2016","unstructured":"Robinson P, Kasembeli M, Bharadwaj U, Engineer N, Eckols KT, Tweardy DJ (2016) Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. Biomed Res Int 2016:1\u20139. https:\/\/doi.org\/10.1155\/2016\/1959270","journal-title":"Biomed Res Int"},{"key":"9940_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CMAR.S186696","volume":"11","author":"DS El-Agamy","year":"2018","unstructured":"El-Agamy DS, El-Harbi KM, Khoshhal S, Ahmed N, Elkablawy MA, Shaaban AA, Abo-Haded HM (2018) Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK\/NF-kB signaling pathways. Cancer Manag Res Volume 11:47\u201361. https:\/\/doi.org\/10.2147\/CMAR.S186696","journal-title":"Cancer Manag Res Volume"},{"key":"9940_CR55","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/cvr\/cvs230","volume":"96","author":"W Chu","year":"2012","unstructured":"Chu W, Li C, Qu X, Zhao D, Wang X, Yu X, Cai F, Liang H, Zhang Y, Zhao X, Li B, Qiao G, Dong D, Lu Y, Du Z, Yang B (2012) Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome. Cardiovasc Res 96:90\u201398. https:\/\/doi.org\/10.1093\/cvr\/cvs230","journal-title":"Cardiovasc Res"},{"key":"9940_CR56","doi-asserted-by":"publisher","first-page":"33787","DOI":"10.1038\/srep33787","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wu X, Li Y, Zhang H, Li Z, Zhang Y, Zhang L, Ju J, Liu X, Chen X, Glybochko PV, Nikolenko V, Kopylov P, Xu C, Yang B (2016) Endothelial to mesenchymal transition contributes to arsenic-trioxide-induced cardiac fibrosis. Sci Rep 6:33787. https:\/\/doi.org\/10.1038\/srep33787","journal-title":"Sci Rep"},{"key":"9940_CR57","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50. https:\/\/doi.org\/10.1186\/s40425-016-0152-y","journal-title":"J Immunother Cancer"},{"key":"9940_CR58","doi-asserted-by":"publisher","unstructured":"Geng Y, Liu X, Liang J, Habiel DM, Vrishika K, Coelho AL, Deng N, Xie T, Wang Y, Liu N, Huang G, Kurkciyan A, Liu Z, Tang J, Hogaboam CM, Jiang D, Noble PW (2019) PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.125326","DOI":"10.1172\/jci.insight.125326"},{"key":"9940_CR59","doi-asserted-by":"publisher","first-page":"S4323","DOI":"10.21037\/jtd.2018.10.07","volume":"10","author":"M Delgobo","year":"2018","unstructured":"Delgobo M, Frantz S (2018) Heart failure in cancer: role of checkpoint inhibitors. J Thorac Dis 10:S4323\u2013S4334. https:\/\/doi.org\/10.21037\/jtd.2018.10.07","journal-title":"J Thorac Dis"},{"key":"9940_CR60","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00059-016-4469-6","volume":"41","author":"B Maisch","year":"2016","unstructured":"Maisch B (2016) Alcoholic cardiomyopathy. Herz 41:484\u2013493. https:\/\/doi.org\/10.1007\/s00059-016-4469-6","journal-title":"Herz"},{"key":"9940_CR61","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/ijms17101651","volume":"17","author":"J Fern\u00e1ndez-Sol\u00e0","year":"2016","unstructured":"Fern\u00e1ndez-Sol\u00e0 J, Planavila Porta A (2016) New treatment strategies for alcohol-induced heart damage. Int J Mol Sci 17:1651. https:\/\/doi.org\/10.3390\/ijms17101651","journal-title":"Int J Mol Sci"},{"key":"9940_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jacc.2017.05.014","volume":"70","author":"O Havakuk","year":"2017","unstructured":"Havakuk O, Rezkalla SH, Kloner RA (2017) The cardiovascular effects of cocaine. J Am Coll Cardiol 70:101\u2013113. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.014","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.hlc.2015.10.019","volume":"25","author":"ED Paratz","year":"2016","unstructured":"Paratz ED, Cunningham NJ, MacIsaac AI (2016) The cardiac complications of methamphetamines. Hear Lung Circ 25:325\u2013332. https:\/\/doi.org\/10.1016\/j.hlc.2015.10.019","journal-title":"Hear Lung Circ"},{"key":"9940_CR64","doi-asserted-by":"publisher","unstructured":"Tsch\u00f6pe C, M\u00fcller I, Xia Y, Savvatis K, Pappritz K, Pinkert S, Lassner D, Heimesaat MM, Spillmann F, Miteva K, Bereswill S, Schultheiss H-P, Fechner H, Pieske B, K\u00fchl U, Van Linthout S (2017) NOD2 (nucleotide-binding oligomerization domain 2) is a major pathogenic mediator of coxsackievirus B3-induced myocarditis. Circ hear fail 10. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.003870","DOI":"10.1161\/CIRCHEARTFAILURE.117.003870"},{"key":"9940_CR65","doi-asserted-by":"publisher","first-page":"e74955","DOI":"10.1371\/journal.pone.0074955","volume":"8","author":"Y Cao","year":"2013","unstructured":"Cao Y, Xu W, Xiong S (2013) Adoptive transfer of regulatory T cells protects against coxsackievirus B3-induced cardiac fibrosis. PLoS One 8:e74955. https:\/\/doi.org\/10.1371\/journal.pone.0074955","journal-title":"PLoS One"},{"key":"9940_CR66","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejphar.2011.02.040","volume":"658","author":"P Chen","year":"2011","unstructured":"Chen P, Xie Y, Shen E, Li GG, Yu Y, Zhang CB, Yang Y, Zou Y, Ge J, Chen R, Chen H (2011) Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-\u03b21 signaling in coxsackievirus B3-induced cardiomyopathy. Eur J Pharmacol 658:168\u2013174. https:\/\/doi.org\/10.1016\/j.ejphar.2011.02.040","journal-title":"Eur J Pharmacol"},{"key":"9940_CR67","doi-asserted-by":"publisher","unstructured":"Hsue PY, Tawakol A (2016) Inflammation and fibrosis in HIV. Circ Cardiovasc Imaging 9. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.004427","DOI":"10.1161\/CIRCIMAGING.116.004427"},{"key":"9940_CR68","doi-asserted-by":"publisher","first-page":"e0187185","DOI":"10.1371\/journal.pone.0187185","volume":"12","author":"J Laurence","year":"2017","unstructured":"Laurence J, Elhadad S, Robison T, Terry H, Varshney R, Woolington S, Ghafoory S, Choi ME, Ahamed J (2017) HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-\u03b21 and can be suppressed by exogenous carbon monoxide. PLoS One 12:e0187185. https:\/\/doi.org\/10.1371\/journal.pone.0187185","journal-title":"PLoS One"},{"key":"9940_CR69","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.lfs.2013.01.003","volume":"92","author":"V Fowlkes","year":"2013","unstructured":"Fowlkes V, Clark J, Fix C, Law BA, Morales MO, Qiao X, Ako-Asare K, Goldsmith JG, Carver W, Murray DB, Goldsmith EC (2013) Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life Sci 92:669\u2013676. https:\/\/doi.org\/10.1016\/j.lfs.2013.01.003","journal-title":"Life Sci"},{"key":"9940_CR70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yjmcc.2015.12.011","volume":"90","author":"I Russo","year":"2016","unstructured":"Russo I, Frangogiannis NG (2016) Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 90:84\u201393. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.12.011","journal-title":"J Mol Cell Cardiol"},{"key":"9940_CR71","doi-asserted-by":"publisher","unstructured":"Yuan H, Fan Y, Wang Y, Gao T, Shao Y, Zhao B, Li H, Xu C, Wei C (2019) Calcium-sensing receptor promotes high glucose-induced myocardial fibrosis via upregulation of the TGF-\u03b21\/Smads pathway in cardiac fibroblasts. Mol Med Rep. https:\/\/doi.org\/10.3892\/mmr.2019.10330","DOI":"10.3892\/mmr.2019.10330"},{"key":"9940_CR72","doi-asserted-by":"publisher","unstructured":"Mitrut R, Stepan AE, Pirici D Histopathological aspects of the myocardium in dilated cardiomyopathy. Curr Heal Sci J 44:243\u2013249. https:\/\/doi.org\/10.12865\/CHSJ.44.03.07","DOI":"10.12865\/CHSJ.44.03.07"},{"key":"9940_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/jcp.2005.026443","volume":"59","author":"KS Cunningham","year":"2006","unstructured":"Cunningham KS (2006) An approach to endomyocardial biopsy interpretation. J Clin Pathol 59:121\u2013129. https:\/\/doi.org\/10.1136\/jcp.2005.026443","journal-title":"J Clin Pathol"},{"key":"9940_CR74","doi-asserted-by":"publisher","unstructured":"Liu T, Song D, Dong J, Zhu P, Liu J, Liu W, Ma X, Zhao L, Ling S (2017) Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. Front Physiol 8. https:\/\/doi.org\/10.3389\/fphys.2017.00238","DOI":"10.3389\/fphys.2017.00238"},{"key":"9940_CR75","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","volume":"65","author":"B L\u00f3pez","year":"2015","unstructured":"L\u00f3pez B, Gonz\u00e1lez A, Ravassa S, Beaumont J, Moreno MU, San Jos\u00e9 G, Querejeta R, D\u00edez J (2015) Circulating biomarkers of myocardial fibrosis. J Am Coll Cardiol 65:2449\u20132456. https:\/\/doi.org\/10.1016\/j.jacc.2015.04.026","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR76","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1253\/circj.CJ-11-0568","volume":"75","author":"T Aoki","year":"2011","unstructured":"Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H (2011) Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Circ J 75:2605\u20132613. https:\/\/doi.org\/10.1253\/circj.CJ-11-0568","journal-title":"Circ J"},{"key":"9940_CR77","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","volume":"5","author":"K Strimbu","year":"2010","unstructured":"Strimbu K, Tavel JA (2010) What are biomarkers? Curr Opin HIV AIDS 5:463\u2013466. https:\/\/doi.org\/10.1097\/COH.0b013e32833ed177","journal-title":"Curr Opin HIV AIDS"},{"key":"9940_CR78","doi-asserted-by":"publisher","first-page":"15946","DOI":"10.1038\/s41598-017-16290-9","volume":"7","author":"W-Y Seo","year":"2017","unstructured":"Seo W-Y, Kim J-H, Baek D-S, Kim S-J, Kang S, Yang WS, Song J-A, Lee M-S, Kim S, Kim Y-S (2017) Production of recombinant human procollagen type I C-terminal propeptide and establishment of a sandwich ELISA for quantification. Sci Rep 7:15946. https:\/\/doi.org\/10.1038\/s41598-017-16290-9","journal-title":"Sci Rep"},{"key":"9940_CR79","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/HYPERTENSIONAHA.112.196113","volume":"60","author":"B L\u00f3pez","year":"2012","unstructured":"L\u00f3pez B, Querejeta R, Gonz\u00e1lez A, Larman M, D\u00edez J (2012) Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure. Hypertension 60:677\u2013683. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.196113","journal-title":"Hypertension"},{"key":"9940_CR80","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","volume":"112","author":"H Izawa","year":"2005","unstructured":"Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M (2005) Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy. Circulation 112:2940\u20132945. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.571653","journal-title":"Circulation"},{"key":"9940_CR81","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1017\/S1047951113001820","volume":"25","author":"BD Kaufman","year":"2015","unstructured":"Kaufman BD, Videon N, Zhang X, Harris MA, Shaddy RE, Goldmuntz E (2015) Procollagen type III amino-terminal propeptide: a serum biomarker of left ventricular remodelling in paediatric dilated cardiomyopathy. Cardiol Young 25:228\u2013236. https:\/\/doi.org\/10.1017\/S1047951113001820","journal-title":"Cardiol Young"},{"key":"9940_CR82","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/ijms19020379","volume":"19","author":"S Sciacchitano","year":"2018","unstructured":"Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco G, Bellotti C, Salehi L, Ricci A (2018) Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int J Mol Sci 19:379. https:\/\/doi.org\/10.3390\/ijms19020379","journal-title":"Int J Mol Sci"},{"key":"9940_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","volume":"3","author":"L Calvier","year":"2015","unstructured":"Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, S\u00e1daba JR, Zannad F, Rossignol P, L\u00f3pez-Andr\u00e9s N (2015) The impact of Galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Hear Fail 3:59\u201367. https:\/\/doi.org\/10.1016\/j.jchf.2014.08.002","journal-title":"JACC Hear Fail"},{"key":"9940_CR84","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","volume":"185","author":"AC MacKinnon","year":"2012","unstructured":"MacKinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T (2012) Regulation of transforming growth factor-\u03b21\u2013driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185:537\u2013546. https:\/\/doi.org\/10.1164\/rccm.201106-0965OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9940_CR85","doi-asserted-by":"publisher","first-page":"17007","DOI":"10.1038\/srep17007","volume":"5","author":"C-K Wu","year":"2015","unstructured":"Wu C-K, Su M-Y, Lee J-K, Chiang F-T, Hwang J-J, Lin J-L, Chen J-J, Liu F-T, Tsai C-T (2015) Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep 5:17007. https:\/\/doi.org\/10.1038\/srep17007","journal-title":"Sci Rep"},{"key":"9940_CR86","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.bbamcr.2014.12.001","volume":"1853","author":"X Song","year":"2015","unstructured":"Song X, Qian X, Shen M, Jiang R, Wagner MB, Ding G, Chen G, Shen B (2015) Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta, Mol Cell Res 1853:513\u2013521. https:\/\/doi.org\/10.1016\/j.bbamcr.2014.12.001","journal-title":"Biochim Biophys Acta, Mol Cell Res"},{"key":"9940_CR87","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7150\/thno.22196","volume":"8","author":"N Suthahar","year":"2018","unstructured":"Suthahar N, Meijers WC, Sillj\u00e9 HHW, Ho JE, Liu F-T, de Boer RA (2018) Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics 8:593\u2013609. https:\/\/doi.org\/10.7150\/thno.22196","journal-title":"Theranostics"},{"key":"9940_CR88","doi-asserted-by":"publisher","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","volume":"296","author":"Y-H Liu","year":"2009","unstructured":"Liu Y-H, D\u2019Ambrosio M, Liao T, Peng H, Rhaleb N-E, Sharma U, Andr\u00e9 S, Gabius H-J, Carretero OA (2009) N -acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin. Am J Physiol Circ Physiol 296:H404\u2013H412. https:\/\/doi.org\/10.1152\/ajpheart.00747.2008","journal-title":"Am J Physiol Circ Physiol"},{"key":"9940_CR89","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1161\/HYPERTENSIONAHA.118.11874","volume":"73","author":"E Mart\u00ednez-Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez-Mart\u00ednez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, L\u00f3pez B, Fern\u00e1ndez-Celis A, Querejeta R, Santamaria E, Fern\u00e1ndez-Irigoyen J, R\u00e1bago G, Moreno MU, Jaisser F, D\u00edez J, Gonz\u00e1lez A, L\u00f3pez-Andr\u00e9s N (2019) CT-1 (cardiotrophin-1)-Gal-3 (galectin-3) axis in cardiac fibrosis and inflammation. Hypertension 73:602\u2013611. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11874","journal-title":"Hypertension"},{"key":"9940_CR90","doi-asserted-by":"publisher","first-page":"205","DOI":"10.11152\/mu-1456","volume":"20","author":"L Agoston-Coldea","year":"2018","unstructured":"Agoston-Coldea L, Bheecarry K, Petra C, Strambu L, Ober C, Revnic R, Lupu S, Mocan T, Fodor D (2018) The value of global longitudinal strain and galectin-3 for predicting cardiovascular events in patients with severe aortic stenosis. Med Ultrason 20:205. https:\/\/doi.org\/10.11152\/mu-1456","journal-title":"Med Ultrason"},{"key":"9940_CR91","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","volume":"60","author":"JE Ho","year":"2012","unstructured":"Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D (2012) Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60:1249\u20131256. https:\/\/doi.org\/10.1016\/j.jacc.2012.04.053","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR92","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/07853890.2010.538080","volume":"43","author":"RA de Boer","year":"2011","unstructured":"de Boer RA, Lok DJA, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60\u201368. https:\/\/doi.org\/10.3109\/07853890.2010.538080","journal-title":"Ann Med"},{"key":"9940_CR93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.02.008","volume":"184","author":"G Vergaro","year":"2015","unstructured":"Vergaro G, Del Franco A, Giannoni A, Prontera C, Ripoli A, Barison A, Masci PG, Aquaro GD, Cohen Solal A, Padeletti L, Passino C, Emdin M (2015) Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int J Cardiol 184:96\u2013100. https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.008","journal-title":"Int J Cardiol"},{"key":"9940_CR94","doi-asserted-by":"publisher","unstructured":"Villacorta H, Maisel AS (2015) Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol. https:\/\/doi.org\/10.5935\/abc.20150151","DOI":"10.5935\/abc.20150151"},{"key":"9940_CR95","doi-asserted-by":"crossref","unstructured":"Lupu S, Agoston-Coldea L (2015) Soluble ST2 in ventricular dysfunction. Pp 139\u2013159","DOI":"10.1016\/bs.acc.2014.12.005"},{"key":"9940_CR96","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","volume":"63","author":"A Bayes-Genis","year":"2014","unstructured":"Bayes-Genis A, de Antonio M, Vila J, Pe\u00f1afiel J, Gal\u00e1n A, Barallat J, Zamora E, Urrutia A, Lup\u00f3n J (2014) Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J Am Coll Cardiol 63:158\u2013166. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.087","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR97","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/eurjhf\/hfs130","volume":"14","author":"R Santhanakrishnan","year":"2012","unstructured":"Santhanakrishnan R, Chong JPC, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Richards AM, Lam CSP (2012) Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 14:1338\u20131347. https:\/\/doi.org\/10.1093\/eurjhf\/hfs130","journal-title":"Eur J Heart Fail"},{"key":"9940_CR98","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cardfail.2013.01.010","volume":"19","author":"Y-C Wang","year":"2013","unstructured":"Wang Y-C, Yu C-C, Chiu F-C, Tsai C-T, Lai L-P, Hwang J-J, Lin J-L (2013) Soluble ST2 as a biomarker for detecting stable heart failure with a Normal ejection fraction in hypertensive patients. J Card Fail 19:163\u2013168. https:\/\/doi.org\/10.1016\/j.cardfail.2013.01.010","journal-title":"J Card Fail"},{"key":"9940_CR99","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/bmm.13.116","volume":"8","author":"L Agoston-Coldea","year":"2014","unstructured":"Agoston-Coldea L, Lupu S, Hicea S, Paradis A, Mocan T (2014) Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomark Med 8:95\u2013106. https:\/\/doi.org\/10.2217\/bmm.13.116","journal-title":"Biomark Med"},{"key":"9940_CR100","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.hjc.2017.03.006","volume":"58","author":"C Wojciechowska","year":"2017","unstructured":"Wojciechowska C, Romuk E, Nowalany-Kozielska E, Jache\u0107 W (2017) Serum galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hell J Cardiol 58:350\u2013359. https:\/\/doi.org\/10.1016\/j.hjc.2017.03.006","journal-title":"Hell J Cardiol"},{"key":"9940_CR101","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cjca.2019.02.016","volume":"35","author":"H You","year":"2019","unstructured":"You H, Jiang W, Jiao M, Wang X, Jia L, You S, Li Y, Wen H, Jiang H, Yuan H, Huang J, Qiao B, Yang Y, Jin M, Wang Y, Du J (2019) Association of soluble ST2 serum levels with outcomes in pediatric dilated cardiomyopathy. Can J Cardiol 35:727\u2013735. https:\/\/doi.org\/10.1016\/j.cjca.2019.02.016","journal-title":"Can J Cardiol"},{"key":"9940_CR102","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10408363.2019.1615034","volume":"56","author":"S Desmedt","year":"2019","unstructured":"Desmedt S, Desmedt V, De Vos L, Delanghe JR, Speeckaert R, Speeckaert MM (2019) Growth differentiation factor 15: a novel biomarker with high clinical potential. Crit Rev Clin Lab Sci 56:333\u2013350. https:\/\/doi.org\/10.1080\/10408363.2019.1615034","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9940_CR103","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3109\/1354750X.2010.510580","volume":"15","author":"F Wang","year":"2010","unstructured":"Wang F, Guo Y, Yu H, Zheng L, Mi L, Gao W (2010) Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomarkers 15:671\u2013676. https:\/\/doi.org\/10.3109\/1354750X.2010.510580","journal-title":"Biomarkers"},{"key":"9940_CR104","doi-asserted-by":"publisher","first-page":"184945441775173","DOI":"10.1177\/1849454417751735","volume":"7","author":"N Nair","year":"2018","unstructured":"Nair N, Gongora E (2018) Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy. J Circ Biomarkers 7:184945441775173. https:\/\/doi.org\/10.1177\/1849454417751735","journal-title":"J Circ Biomarkers"},{"key":"9940_CR105","doi-asserted-by":"publisher","first-page":"88","DOI":"10.11909\/j.issn.1671-5411.2016.01.002","volume":"13","author":"F-F Wang","year":"2016","unstructured":"Wang F-F, Chen B-X, Yu H-Y, Mi L, Li Z-J, Gao W (2016) Correlation between growth differentiation factor-15 and collagen metabolism indicators in patients with myocardial infarction and heart failure. J Geriatr Cardiol 13:88\u201393. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2016.01.002","journal-title":"J Geriatr Cardiol"},{"key":"9940_CR106","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3945\/an.116.013839","volume":"8","author":"J Cui","year":"2017","unstructured":"Cui J, Zhou B, Ross SA, Zempleni J (2017) Nutrition, microRNAs, and human health. Adv Nutr An Int Rev J 8:105\u2013112. https:\/\/doi.org\/10.3945\/an.116.013839","journal-title":"Adv Nutr An Int Rev J"},{"key":"9940_CR107","doi-asserted-by":"crossref","unstructured":"Huang W (2017) MicroRNAs: biomarkers, diagnostics, and therapeutics. Pp 57\u201367","DOI":"10.1007\/978-1-4939-7046-9_4"},{"key":"9940_CR108","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12872-017-0520-7","volume":"17","author":"W Cao","year":"2017","unstructured":"Cao W, Shi P, Ge J-J (2017) miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1\/STAT3 pathway. BMC Cardiovasc Disord 17:88. https:\/\/doi.org\/10.1186\/s12872-017-0520-7","journal-title":"BMC Cardiovasc Disord"},{"key":"9940_CR109","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1159\/000479995","volume":"42","author":"J Yuan","year":"2017","unstructured":"Yuan J, Chen H, Ge D, Xu Y, Xu H, Yang Y, Gu M, Zhou Y, Zhu J, Ge T, Chen Q, Gao Y, Wang Y, Li X, Zhao Y (2017) Mir-21 promotes cardiac fibrosis after myocardial infarction via targeting Smad7. Cell Physiol Biochem 42:2207\u20132219. https:\/\/doi.org\/10.1159\/000479995","journal-title":"Cell Physiol Biochem"},{"key":"9940_CR110","doi-asserted-by":"publisher","first-page":"e56280","DOI":"10.1371\/journal.pone.0056280","volume":"8","author":"H Br\u00f8nnum","year":"2013","unstructured":"Br\u00f8nnum H, Andersen DC, Schneider M, Sandberg MB, Eskildsen T, Nielsen SB, Kalluri R, Sheikh SP (2013) miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving programmed cell death 4 and sprouty-1. PLoS one 8:e56280. https:\/\/doi.org\/10.1371\/journal.pone.0056280","journal-title":"PLoS one"},{"key":"9940_CR111","doi-asserted-by":"publisher","unstructured":"Li X, Liu CY, Li YS, Xu J, Li DG, Han D (2016) Deep RNA sequencing elucidates microRNA-regulated molecular pathways in ischemic cardiomyopathy and nonischemic cardiomyopathy. Genet Mol Res:15. https:\/\/doi.org\/10.4238\/gmr.15027465","DOI":"10.4238\/gmr.15027465"},{"key":"9940_CR112","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.jacc.2014.03.064","volume":"64","author":"Y Dai","year":"2014","unstructured":"Dai Y, Dai D, Mehta JL (2014) MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker. J Am Coll Cardiol 64:2181. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.064","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR113","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41467-017-01737-4","volume":"8","author":"Y Sassi","year":"2017","unstructured":"Sassi Y, Avramopoulos P, Ramanujam D, Gr\u00fcter L, Werfel S, Giosele S, Brunner A-D, Esfandyari D, Papadopoulou AS, De Strooper B, H\u00fcbner N, Kumarswamy R, Thum T, Yin X, Mayr M, Laggerbauer B, Engelhardt S (2017) Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun 8:1614. https:\/\/doi.org\/10.1038\/s41467-017-01737-4","journal-title":"Nat Commun"},{"key":"9940_CR114","doi-asserted-by":"publisher","first-page":"e0171957","DOI":"10.1371\/journal.pone.0171957","volume":"12","author":"Y Yamada","year":"2017","unstructured":"Yamada Y, Takanashi M, Sudo K, Ueda S, Ohno S, Kuroda M (2017) Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis. PLoS One 12:e0171957. https:\/\/doi.org\/10.1371\/journal.pone.0171957","journal-title":"PLoS One"},{"key":"9940_CR115","doi-asserted-by":"publisher","first-page":"e0197688","DOI":"10.1371\/journal.pone.0197688","volume":"13","author":"CA Drummond","year":"2018","unstructured":"Drummond CA, Fan X, Haller ST, Kennedy DJ, Liu J, Tian J (2018) Na\/K-ATPase signaling mediates miR-29b-3p regulation and cardiac fibrosis formation in mice with chronic kidney disease. PLoS One 13:e0197688. https:\/\/doi.org\/10.1371\/journal.pone.0197688","journal-title":"PLoS One"},{"key":"9940_CR116","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.bbadis.2019.06.004","volume":"1865","author":"J Liang","year":"2019","unstructured":"Liang J, Zou X, Fang X, Xu J, Xiao Z, Zhu J, Li H, Yang J, Zeng N, Yuan S, Pan R, Fu Y, Zhang M, Luo J, Wang S, Shan Z (2019) The Smad3-miR-29b\/miR-29c axis mediates the protective effect of macrophage migration inhibitory factor against cardiac fibrosis. Biochim Biophys Acta Mol basis Dis 1865:2441\u20132450. https:\/\/doi.org\/10.1016\/j.bbadis.2019.06.004","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"9940_CR117","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/j.1742-4658.2010.07632.x","volume":"277","author":"X Jiang","year":"2010","unstructured":"Jiang X, Tsitsiou E, Herrick SE, Lindsay MA (2010) MicroRNAs and the regulation of fibrosis. FEBS J 277:2015\u20132021. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07632.x","journal-title":"FEBS J"},{"key":"9940_CR118","doi-asserted-by":"publisher","unstructured":"Chen L, Ji Q, Zhu H, Ren Y, Fan Z, Tian N (2018) miR-30a attenuates cardiac fibrosis in rats with myocardial infarction by inhibiting CTGF. Exp Ther Med. https:\/\/doi.org\/10.3892\/etm.2018.5952","DOI":"10.3892\/etm.2018.5952"},{"key":"9940_CR119","doi-asserted-by":"publisher","first-page":"e0139858","DOI":"10.1371\/journal.pone.0139858","volume":"10","author":"A Angelini","year":"2015","unstructured":"Angelini A, Li Z, Mericskay M, Decaux J-F (2015) Regulation of connective tissue growth factor and cardiac fibrosis by an SRF\/MicroRNA-133a axis. PLoS One 10:e0139858. https:\/\/doi.org\/10.1371\/journal.pone.0139858","journal-title":"PLoS One"},{"key":"9940_CR120","doi-asserted-by":"publisher","unstructured":"Li N, Zhou H, Tang Q (2018) miR-133: a suppressor of cardiac remodeling? Front Pharmacol 9. https:\/\/doi.org\/10.3389\/fphar.2018.00903","DOI":"10.3389\/fphar.2018.00903"},{"key":"9940_CR121","doi-asserted-by":"publisher","unstructured":"Wang DS, Zhang HQ, Zhang B, Yuan ZB, Yu ZK, Yang T, Zhang SQ, Liu Y, Jia XX (2016) miR-133 inhibits pituitary tumor cell migration and invasion via down-regulating FOXC1 expression. Genet Mol res 15. https:\/\/doi.org\/10.4238\/gmr.15017453","DOI":"10.4238\/gmr.15017453"},{"key":"9940_CR122","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/jcmm.12218","volume":"18","author":"S Chen","year":"2014","unstructured":"Chen S, Puthanveetil P, Feng B, Matkovich SJ, Dorn GW, Chakrabarti S (2014) Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 18:415\u2013421. https:\/\/doi.org\/10.1111\/jcmm.12218","journal-title":"J Cell Mol Med"},{"key":"9940_CR123","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11010-012-1546-x","volume":"376","author":"N Nair","year":"2013","unstructured":"Nair N, Kumar S, Gongora E, Gupta S (2013) Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem 376:33\u201340. https:\/\/doi.org\/10.1007\/s11010-012-1546-x","journal-title":"Mol Cell Biochem"},{"key":"9940_CR124","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ejhf.223","volume":"17","author":"LL Wong","year":"2015","unstructured":"Wong LL, Armugam A, Sepramaniam S, Karolina DS, Lim KY, Lim JY, Chong JPC, Ng JYX, Chen Y-T, Chan MMY, Chen Z, Yeo PSD, Ng TP, Ling LH, Sim D, Leong KTG, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Lam CSP, Jeyaseelan K, Richards AM (2015) Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 17:393\u2013404. https:\/\/doi.org\/10.1002\/ejhf.223","journal-title":"Eur J Heart Fail"},{"key":"9940_CR125","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ejhf.244","volume":"17","author":"CJ Watson","year":"2015","unstructured":"Watson CJ, Gupta SK, O\u2019Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T (2015) MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 17:405\u2013415. https:\/\/doi.org\/10.1002\/ejhf.244","journal-title":"Eur J Heart Fail"},{"key":"9940_CR126","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacc.2010.11.013","volume":"57","author":"N Mewton","year":"2011","unstructured":"Mewton N, Liu CY, Croisille P, Bluemke D, Lima JAC (2011) Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57:891\u2013903. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.013","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR127","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ehjci\/jeu182","volume":"16","author":"LM Iles","year":"2015","unstructured":"Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, Taylor AJ (2015) Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging 16:14\u201322. https:\/\/doi.org\/10.1093\/ehjci\/jeu182","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"9940_CR128","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mrm.20110","volume":"52","author":"DR Messroghli","year":"2004","unstructured":"Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP (2004) Modified Look-Locker inversion recovery (MOLLI) for high-resolutionT1 mapping of the heart. Magn Reson Med 52:141\u2013146. https:\/\/doi.org\/10.1002\/mrm.20110","journal-title":"Magn Reson Med"},{"key":"9940_CR129","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/01.CIR.0000078641.19365.4C","volume":"108","author":"JA McCrohon","year":"2003","unstructured":"McCrohon JA, Moon JCC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJS, Pennell DJ (2003) Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108:54\u201359. https:\/\/doi.org\/10.1161\/01.CIR.0000078641.19365.4C","journal-title":"Circulation"},{"key":"9940_CR130","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2006.07.049","volume":"48","author":"RG Assomull","year":"2006","unstructured":"Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ (2006) Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48:1977\u20131985. https:\/\/doi.org\/10.1016\/j.jacc.2006.07.049","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR131","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.crad.2015.05.007","volume":"70","author":"X Duan","year":"2015","unstructured":"Duan X, Li J, Zhang Q, Zeng Z, Luo Y, Jiang J, Chen Y (2015) Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients: a meta-analysis. Clin Radiol 70:999\u20131008. https:\/\/doi.org\/10.1016\/j.crad.2015.05.007","journal-title":"Clin Radiol"},{"key":"9940_CR132","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.mri.2013.10.011","volume":"32","author":"M Machii","year":"2014","unstructured":"Machii M, Satoh H, Shiraki K, Saotome M, Urushida T, Katoh H, Takehara Y, Sakahara H, Ohtani H, Wakabayashi Y, Ukigai H, Tawarahara K, Hayashi H (2014) Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome. Magn Reson Imaging 32:118\u2013124. https:\/\/doi.org\/10.1016\/j.mri.2013.10.011","journal-title":"Magn Reson Imaging"},{"key":"9940_CR133","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/0284185115580840","volume":"57","author":"M Tachi","year":"2016","unstructured":"Tachi M, Amano Y, Inui K, Takeda M, Yamada F, Asai K, Kumita S (2016) Relationship of postcontrast myocardial T1 value and delayed enhancement to reduced cardiac function and serious arrhythmia in dilated cardiomyopathy with left ventricular ejection fraction less than 35%. Acta Radiol 57:430\u2013436. https:\/\/doi.org\/10.1177\/0284185115580840","journal-title":"Acta Radiol"},{"key":"9940_CR134","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jcmg.2017.08.005","volume":"10","author":"AR Patel","year":"2017","unstructured":"Patel AR, Kramer CM (2017) Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging 10:1180\u20131193. https:\/\/doi.org\/10.1016\/j.jcmg.2017.08.005","journal-title":"JACC Cardiovasc Imaging"},{"key":"9940_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12968-015-0221-2","volume":"18","author":"RJ Taylor","year":"2015","unstructured":"Taylor RJ, Umar F, Lin ELS, Ahmed A, Moody WE, Mazur W, Stegemann B, Townend JN, Steeds RP, Leyva F (2015) Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy. J Cardiovasc Magn Reson 18:1. https:\/\/doi.org\/10.1186\/s12968-015-0221-2","journal-title":"J Cardiovasc Magn Reson"},{"key":"9940_CR136","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3978\/j.issn.2223-3652.2013.09.03","volume":"4","author":"CL Jellis","year":"2014","unstructured":"Jellis CL, Kwon DH (2014) Myocardial T1 mapping: modalities and clinical applications. Cardiovasc Diagn Ther 4:126\u2013137. https:\/\/doi.org\/10.3978\/j.issn.2223-3652.2013.09.03","journal-title":"Cardiovasc Diagn Ther"},{"key":"9940_CR137","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1148\/rg.342125121","volume":"34","author":"JR Burt","year":"2014","unstructured":"Burt JR, Zimmerman SL, Kamel IR, Halushka M, Bluemke DA (2014) Myocardial T1 mapping: techniques and potential applications. RadioGraphics 34:377\u2013395. https:\/\/doi.org\/10.1148\/rg.342125121","journal-title":"RadioGraphics"},{"key":"9940_CR138","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.109.930636","volume":"122","author":"AS Flett","year":"2010","unstructured":"Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC (2010) Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis. Circulation 122:138\u2013144. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.930636","journal-title":"Circulation"},{"key":"9940_CR139","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/CIRCULATIONAHA.116.026910","volume":"135","author":"BP Halliday","year":"2017","unstructured":"Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, Pennell DJ, Prasad SK (2017) Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 135:2106\u20132115. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026910","journal-title":"Circulation"},{"key":"9940_CR140","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jacc.2012.02.070","volume":"60","author":"I Klem","year":"2012","unstructured":"Klem I, Weinsaft JW, Bahnson TD, Hegland D, Kim HW, Hayes B, Parker MA, Judd RM, Kim RJ (2012) Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol 60:408\u2013420. https:\/\/doi.org\/10.1016\/j.jacc.2012.02.070","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR141","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0735-1097(19)32157-6","volume":"73","author":"S Ota","year":"2019","unstructured":"Ota S (2019) The pattern of myocardial fibrosis detected by cardiovascular magnetic resonance imaging provides prognostic information in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 73:1551. https:\/\/doi.org\/10.1016\/S0735-1097(19)32157-6","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR142","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11604-010-0433-1","volume":"28","author":"AK Kono","year":"2010","unstructured":"Kono AK, Ishii K, Kumagai H, Taniguchi Y, Kajiya T, Sugimura K (2010) Late gadolinium enhancement on cardiac magnetic resonance imaging: is it associated with a higher incidence of nonsustained ventricular tachycardia in patients with idiopathic dilated cardiomyopathy? Jpn J Radiol 28:355\u2013361. https:\/\/doi.org\/10.1007\/s11604-010-0433-1","journal-title":"Jpn J Radiol"},{"key":"9940_CR143","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1532-429X-13-29","volume":"13","author":"F Leyva","year":"2011","unstructured":"Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, Auricchio A (2011) Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 13:29. https:\/\/doi.org\/10.1186\/1532-429X-13-29","journal-title":"J Cardiovasc Magn Reson"},{"key":"9940_CR144","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/eurheartj\/ehr391","volume":"33","author":"DP Leong","year":"2012","unstructured":"Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, Sullivan T, Worthley SG, De Pasquale CG, Sanders P, Selvanayagam JB (2012) Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J 33:640\u2013648. https:\/\/doi.org\/10.1093\/eurheartj\/ehr391","journal-title":"Eur Heart J"},{"key":"9940_CR145","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jacc.2012.05.054","volume":"60","author":"F Leyva","year":"2012","unstructured":"Leyva F, Taylor RJ, Foley PWX, Umar F, Mulligan LJ, Patel K, Stegemann B, Haddad T, Smith REA, Prasad SK (2012) Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 60:1659\u20131667. https:\/\/doi.org\/10.1016\/j.jacc.2012.05.054","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR146","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jama.2013.1363","volume":"309","author":"A Gulati","year":"2013","unstructured":"Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TDH, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O\u2019Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK (2013) Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309:896. https:\/\/doi.org\/10.1001\/jama.2013.1363","journal-title":"JAMA"},{"key":"9940_CR147","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcmg.2015.12.001","volume":"9","author":"VO Puntmann","year":"2016","unstructured":"Puntmann VO, Carr-White G, Jabbour A, Yu C-Y, Gebker R, Kelle S, Hinojar R, Doltra A, Varma N, Child N, Rogers T, Suna G, Arroyo Ucar E, Goodman B, Khan S, Dabir D, Herrmann E, Zeiher AM, Nagel E (2016) T1-mapping and outcome in nonischemic cardiomyopathy. JACC Cardiovasc Imaging 9:40\u201350. https:\/\/doi.org\/10.1016\/j.jcmg.2015.12.001","journal-title":"JACC Cardiovasc Imaging"},{"key":"9940_CR148","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12968-018-0466-7","volume":"20","author":"S-H Pi","year":"2018","unstructured":"Pi S-H, Kim SM, Choi J-O, Kim EK, Chang S-A, Choe YH, Lee S-C, Jeon E-S (2018) Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction. J Cardiovasc Magn Reson 20:36. https:\/\/doi.org\/10.1186\/s12968-018-0466-7","journal-title":"J Cardiovasc Magn Reson"},{"key":"9940_CR149","doi-asserted-by":"publisher","unstructured":"Oh J, Hong YJ, Ha J, Chun KH, Kim H, Lee CJ, Kim YJ, Choi BW, Kang SM (2019) P3555Lower native T1, extracellular volume and T2 on cardiac magnetic resonance imaging is related to more left ventricular reverse remodeling in nonischemic dilated cardiomyopathy. Eur heart J 40. https:\/\/doi.org\/10.1093\/eurheartj\/ehz745.0418","DOI":"10.1093\/eurheartj\/ehz745.0418"},{"key":"9940_CR150","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL (2013) 2013 ACCF\/AHA guideline for the management of heart failure. J Am Coll Cardiol 62:e147\u2013e239. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019","journal-title":"J Am Coll Cardiol"},{"key":"9940_CR151","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129\u20132200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"9940_CR152","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.tcm.2017.12.006","volume":"28","author":"V Russo","year":"2018","unstructured":"Russo V, Papa AA, Williams EA, Rago A, Palladino A, Politano L, Nigro G (2018) ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies. Trends Cardiovasc Med 28:330\u2013337. https:\/\/doi.org\/10.1016\/j.tcm.2017.12.006","journal-title":"Trends Cardiovasc Med"},{"key":"9940_CR153","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/CIRCRESAHA.116.305381","volume":"116","author":"A Leask","year":"2015","unstructured":"Leask A (2015) Getting to the heart of the matter. Circ Res 116:1269\u20131276. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.305381","journal-title":"Circ Res"},{"key":"9940_CR154","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.molmed.2015.12.006","volume":"22","author":"EA Rog-Zielinska","year":"2016","unstructured":"Rog-Zielinska EA, Norris RA, Kohl P, Markwald R (2016) The living scar \u2013 cardiac fibroblasts and the injured heart. Trends Mol Med 22:99\u2013114. https:\/\/doi.org\/10.1016\/j.molmed.2015.12.006","journal-title":"Trends Mol Med"},{"key":"9940_CR155","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/heartjnl-2014-306786","volume":"102","author":"J Tietjens","year":"2016","unstructured":"Tietjens J, Teerlink JR (2016) Serelaxin and acute heart failure. Heart 102:95\u201399. https:\/\/doi.org\/10.1136\/heartjnl-2014-306786","journal-title":"Heart"},{"key":"9940_CR156","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yexcr.2017.10.004","volume":"362","author":"X Wu","year":"2018","unstructured":"Wu X, Wang H, Wang Y, Shen H, Tan Y (2018) Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK-5\/Smad2\/3 signaling pathway. Exp Cell Res 362:17\u201327. https:\/\/doi.org\/10.1016\/j.yexcr.2017.10.004","journal-title":"Exp Cell Res"},{"key":"9940_CR157","doi-asserted-by":"publisher","unstructured":"Zhang N, Wei W-Y, Li L-L, Hu C, Tang Q-Z (2018) Therapeutic potential of polyphenols in cardiac fibrosis. Front Pharmacol 9. https:\/\/doi.org\/10.3389\/fphar.2018.00122","DOI":"10.3389\/fphar.2018.00122"},{"key":"9940_CR158","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.yjmcc.2014.07.009","volume":"75","author":"C Xu","year":"2014","unstructured":"Xu C, Hu Y, Hou L, Ju J, Li X, Du N, Guan X, Liu Z, Zhang T, Qin W, Shen N, Bilal MU, Lu Y, Zhang Y, Shan H (2014) \u03b2-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. J Mol Cell Cardiol 75:111\u2013121. https:\/\/doi.org\/10.1016\/j.yjmcc.2014.07.009","journal-title":"J Mol Cell Cardiol"},{"key":"9940_CR159","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00395-009-0071-x","volume":"105","author":"S-H Ihm","year":"2010","unstructured":"Ihm S-H, Chang K, Kim H-Y, Baek SH, Youn H-J, Seung K-B, Kim J-H (2010) Peroxisome proliferator-activated receptor-\u03b3 activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol 105:399\u2013407. https:\/\/doi.org\/10.1007\/s00395-009-0071-x","journal-title":"Basic Res Cardiol"},{"key":"9940_CR160","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/jdi.12153","volume":"5","author":"CY Shim","year":"2014","unstructured":"Shim CY, Song B-W, Cha M-J, Hwang K-C, Park S, Hong G-R, Kang S-M, Lee JE, Ha J-W, Chung N (2014) Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats. J Diabetes Investig 5:362\u2013371. https:\/\/doi.org\/10.1111\/jdi.12153","journal-title":"J Diabetes Investig"},{"key":"9940_CR161","doi-asserted-by":"publisher","first-page":"e0178619","DOI":"10.1371\/journal.pone.0178619","volume":"12","author":"L-X Wang","year":"2017","unstructured":"Wang L-X, Yang X, Yue Y, Fan T, Hou J, Chen G-X, Liang M-Y, Wu Z-K (2017) Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model. PLoS One 12:e0178619. https:\/\/doi.org\/10.1371\/journal.pone.0178619","journal-title":"PLoS One"},{"key":"9940_CR162","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0003-4975(00)01755-0","volume":"70","author":"PA Chaudhry","year":"2000","unstructured":"Chaudhry PA, Mishima T, Sharov VG, Hawkins J, Alferness C, Paone G, Sabbah HN (2000) Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg 70:1275\u20131280. https:\/\/doi.org\/10.1016\/S0003-4975(00)01755-0","journal-title":"Ann Thorac Surg"},{"key":"9940_CR163","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1055\/s-2001-11709","volume":"49","author":"T Doenst","year":"2001","unstructured":"Doenst T, Ahn-Veelken L, Schlensak C, Berchtold-Herz M, Sarai K, Schaefer M, van de Loo A, Beyersdorf F (2001) Left ventricular reduction for idiopathic dilated cardiomyopathy as alternative to transplant - truth or dare?*. Thorac Cardiovasc Surg 49:70\u201374. https:\/\/doi.org\/10.1055\/s-2001-11709","journal-title":"Thorac Cardiovasc Surg"},{"key":"9940_CR164","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/S1010-7940(99)00193-1","volume":"16","author":"A Calafiore","year":"1999","unstructured":"Calafiore A (1999) Surgical treatment of dilated cardiomyopathy with conventional techniques*1. Eur J Cardio-Thoracic Surg 16:S73\u2013S78. https:\/\/doi.org\/10.1016\/S1010-7940(99)00193-1","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"9940_CR165","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1010-7940(00)00322-5","volume":"17","author":"T Isomura","year":"2000","unstructured":"Isomura T, Suma H, Horii T, Sato T, Kikuchi N (2000) Partial left ventriculectomy, ventriculoplasty or valvular surgery for idiopathic dilated cardiomyopathy \u2013 the role of intra-operative echocardiography. Eur J Cardio-Thoracic Surg 17:239\u2013245. https:\/\/doi.org\/10.1016\/S1010-7940(00)00322-5","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"9940_CR166","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.athoracsur.2006.04.096","volume":"82","author":"H Suma","year":"2006","unstructured":"Suma H, Isomura T, Horii T, Nomura F (2006) Septal anterior ventricular exclusion procedure for idiopathic dilated cardiomyopathy. Ann Thorac Surg 82:1344\u20131348. https:\/\/doi.org\/10.1016\/j.athoracsur.2006.04.096","journal-title":"Ann Thorac Surg"},{"key":"9940_CR167","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/jce.13171","volume":"28","author":"J WANG","year":"2017","unstructured":"WANG J, GONG X, CHEN H, QIN S, ZHOU N, SU Y, GE J (2017) Effect of cardiac resynchronization therapy on myocardial fibrosis and relevant cytokines in a canine model with experimental heart failure. J Cardiovasc Electrophysiol 28:438\u2013445. https:\/\/doi.org\/10.1111\/jce.13171","journal-title":"J Cardiovasc Electrophysiol"},{"key":"9940_CR168","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.amjcard.2015.06.022","volume":"116","author":"K Broch","year":"2015","unstructured":"Broch K, Murbr\u00e6ch K, Andreassen AK, Hopp E, Aakhus S, Gullestad L (2015) Contemporary outcome in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 116:952\u2013959. https:\/\/doi.org\/10.1016\/j.amjcard.2015.06.022","journal-title":"Am J Cardiol"},{"key":"9940_CR169","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1071-9164(05)80002-8","volume":"1","author":"PJ Keeling","year":"1995","unstructured":"Keeling PJ, Goldman JH, Slade AKB, Elliott PM, Caforio ALP, Poloniecki J, McKenna WJ (1995) Prognosis of idiopathic dilated cardiomyopathy. J Card Fail 1:337\u2013345. https:\/\/doi.org\/10.1016\/S1071-9164(05)80002-8","journal-title":"J Card Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-09940-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T02:26:08Z","timestamp":1627093568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-09940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":169,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["9940"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-09940-0","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"13 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}